A look at vaginal laser surgery for overactive bladder syndrome.
As any woman who experiences overactive bladder syndrome (OAB) can tell you, worrying about where the nearest rest room is whenever you leave your home can be a continual source of anxiety. In the United States 33% of women report this condition, and in Asia, 53.1%.
Up until now, the most common treatments for OAB included behavior modification, pharmacologic management, injections, and localized nerve stimulation. Recently, study findings published in Menopause, the journal of The North American Menopause Society, suggest that laser treatment for this condition, in particular, the vaginal Erbium YAG laser, can cause less urination frequency and urgency episodes, with a side benefit of reduced vaginal atrophy symptoms.
In a single-center, blinded, randomized sham-controlled study conducted between July 2019 and August 2022, 50 postmenopausal women in Thailand diagnosed with OAB received either one treatment session of vaginal Erbium YAG laser or the sham procedure, with 25 women assigned to each group. The study was conducted at the female pelvic medicine and reconstructive surgery clinic at King Chulalongkorn Memorial Hospital, which is a tertiary referral university hospital in Bangkok, Thailand.
Participants were asked to be enrolled by the lead investigator using a convenience sampling method, with randomization done by computer-generated block randomization. The primary outcome used the Thai version of the Overactive Bladder Symptom Score, while secondary outcomes used included the Thai version Overactive Bladder Questionnaire, which included 25 health-related quality of life items. The Patient Perception of Bladder Condition Questionnaire asked about the patients perception of lower urinary tract symptoms. A bladder diary, vaginal atrophy symptoms (VAS) score and a Vaginal Health Index score (VHI) were also used. All questionnaires were self-administered and collected by a research assistant at initial and follow-up visits.
Outcomes were evaluated 12 weeks after treatment. Investigators reported overall improvement in OAB severity in women receiving the laser treatment compared to the sham group. Improvements included daytime frequency, urgency episodes, and maximum urine volume (assessed by the bladder diary and vaginal atrophy sign and symptoms). Additionally, investigators pointed out that other nonrandomized controlled trials had reported improvement of vaginal atrophy signs and symptoms after use of this laser.
The researchers noted that the strengths of the study included being the first study of its kind using the vaginal laser procedure to treat OAB. However, the study had a short-term follow-up; longer clinical trials and a cost-effective study in the future could add to the veracity of the study findings.
Reference
Chiengthong K, Bunyavejchevin S. Efficacy of Erbium YAG laser treatment in overactive bladder syndrome: a randomized controlled trial. 2023;30(4):00-00. Menopause. doi:10.1097/GME.0000000000002159
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Understanding VTE and bleeding risks in gynecologic noncancer surgery
April 15th 2024Delve into the nuanced risks of venous thromboembolism and major bleeding post-gynecologic noncancer surgery, exploring procedure-specific variations and the implications for thromboprophylaxis strategies.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More